Severe menopausal symptoms linked to cognitive impairment: an exploratory study

Objective: To evaluate the association between menopausal symptoms and cognitive decline in postmenopausal women. Methods: This was a subanalysis of a cross-sectional, observational study conducted among women attending gynecological consultations across nine Latin American countries. The survey inv...

Full description

Autores:
Calle, Andrés
Blümel, Juan E.
Chedraui, Peter
Vallejo, María S.
Belardo, Alejandra
Dextre, Maribel
Elizalde-Cremonte, Alejandra
Escalante, Carlos
Espinoza, María T.
Gómez-Tabares, Gustavo
Monterrosa-Castro, Alvaro
Ñañez, Mónica
Ojeda, Eliana
Rey, Claudia
Rodríguez, Doris
Rodrigues, Marcio A.
Salinas, Carlos
Tserotas, Konstantinos
Aedo, Sócrates
Tipo de recurso:
Article of journal
Fecha de publicación:
2024
Institución:
Universidad de Cartagena
Repositorio:
Repositorio Universidad de Cartagena
Idioma:
OAI Identifier:
oai:repositorio.unicartagena.edu.co:11227/19385
Acceso en línea:
https://hdl.handle.net/11227/19385
Palabra clave:
3. Ciencias Médicas y de la Salud
Terapia hormonal para la menopausia
Síntomas de la menopausia
Escala de evaluación de la menopausia
Deterioro cognitivo leve
Evaluación cognitiva de Montreal
Menopausal hormone therapy
Menopause Rating Scale
Mild cognitive impairment
Montreal Cognitive Assessment.
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
Rights
openAccess
License
https://creativecommons.org/licenses/by-nc/4.0/
Description
Summary:Objective: To evaluate the association between menopausal symptoms and cognitive decline in postmenopausal women. Methods: This was a subanalysis of a cross-sectional, observational study conducted among women attending gynecological consultations across nine Latin American countries. The survey involved late postmenopausal women who were asked to complete a general questionnaire and the Menopause Rating Scale (MRS) to assess menopausal symptoms, with the Montreal Cognitive Assessment used to evaluate cognitive function as an outcome. A Montreal Cognitive Assessment score of less than 21 was used to define women with mild cognitive impairment (MCI). Results: The study included 1,287 postmenopausal women with a mean age of 55.5 years and a mean body mass index of 26.3 kg/m2 . On average, participants had 13.8 years of education and 2.3 ± 1.8 children, with 72.8% reporting having a partner. Additionally, 36.7% ever used menopausal hormone therapy. Regarding lifestyle factors, 50.3% engaged in a sedentary lifestyle, whereas 70.5% had never smoked. 15.3% of women had MCI exhibited significantly more intense menopausal symptoms compared with those without MCI (MRS total score 15.24 ± 12.58 vs 10.53 ± 8.84, respectively, P < 0.001). Logistic regression analysis revealed a significant association between severe menopausal symptoms (MRS total score ≥14 points) and MCI (odds ratio [OR], 1.74; 95% CI, 1.25-2.42). Conversely, a lower body mass index (OR, 0.96; 95% CI, 0.95-0.98), sexual activity (OR, 0.70; 95% CI, 0.51-0.96), physical exercise (OR, 0.55; 95% CI, 0.39-0.76), menopausal hormone therapy use (OR, 0.36; 95% CI, 0.24-0.55), and higher educational level (OR, 0.31; 95% CI, 0.21-0.46) were associated with lower odds for MCI. Conclusion: Severe menopausal symptoms in postmenopausal women were associated with cognitive impairment. This study highlights the intricate interplay between hormonal, lifestyle, and sociodemographic factors and cognitive health.